Participated · Seed · Apr 2026

ViewsML develops an AI-driven virtual biomarker staining platform that virtualizes immunohistochemistry to deliver per-cell spatial biomarker insights from standard H&E slides. The platform is intended to preserve scarce tissue samples while accelerating research, clinical trials, and patient care. ViewsML is building a virtual biomarker library comprised of AI models that extract biomarker information directly from routine pathology images. The company has established strategic collaborations with healthcare institutions, diagnostic companies, and biopharma organizations to drive adoption across research and clinical applications. Led by CEO Kenneth To, ViewsML plans to use newly raised seed capital to commercialize the platform, expand partnerships, advance clinical validation of its virtual biomarker panels, and grow its engineering, scientific, and commercial teams.

Participated · Equity · Oct 2025

StratifAI is a precision oncology company founded in Berlin that applies artificial intelligence to identify prognostic and predictive biomarkers from multimodal clinical data. Its core product, the Polaris™ platform, fuses H&E histology with RNA-Seq gene expression to link spatial tumor signals directly to patient outcomes, speeding up biomarker discovery while lowering associated costs. The company is assembling a large multimodal reference dataset from collected tumor samples to continually expand its portfolio of spatial biomarkers. StratifAI’s first commercial test, Polaris™ Breast, assesses metastasis risk in early breast cancer and is currently undergoing regulatory review in the EU and the United States. Fresh capital is earmarked to complete clinical validation of Polaris™ Breast and to establish a scalable regulatory framework for clinical AI diagnostics. In parallel, the firm is deepening collaborations with oncology centers and pharmaceutical partners to build the clinical evidence required for guideline inclusion and routine practice. By leveraging growing digital pathology data, StratifAI aims to unlock a sizable, under-served market in cancer diagnostics and deliver more individualized and equitable care for patients with solid tumors.

Led · Series A · Feb 2024

Strategikon offers cloud-based solutions that optimize and accelerate the budgeting, planning, outsourcing, and vendor management of clinical trials. Its flagship product, Clinical Maestro, is an end-to-end outsourcing management platform that replaces manual processes and outdated procurement tools while reducing regulatory compliance risk related to vendor oversight. The system was developed by financial and clinical business operations executives with Sponsor and Clinical Service Provider experience. Strategikon serves global pharma and biotech clients across the US, Europe, and Japan. The company is based in San Francisco and is led by CEO Anca Copaescu. Strategikon recently closed an over-subscribed $7.0M Series A1 financing round and plans to use the proceeds to build out sales and customer success teams to support and scale growth. Strategikon Pharma develops Clinical Maestro, a cloud-based platform that modernizes outsourcing for clinical programs by enabling sponsors, vendors, and service providers to plan studies, model and manage clinical contracts systematically. The platform is designed to speed budgeting, sourcing and management while improving accuracy and reducing effort. The company announced the close of a Series A financing to support its growth. The new capital will be used to expand Strategikon's global footprint in Europe and Asia, develop new and enhance existing applications in the Clinical Maestro ecosystem, and expand the breadth and depth of professional services to improve customer experience and support. CEO Anca Copaescu said Clinical Maestro addresses long, unresolved pain points in clinical study outsourcing and financial management and will enable the company to attract new talent.

Participated · Seed · Sep 2023

Tune Insight is a Swiss cybersecurity startup developing privacy-preserving machine learning and interoperability solutions for Electronic Health Records (EHR) in clinical settings. Its current project focuses on a federated learning platform to enable secure, patient-centered research across pediatric emergency departments. The platform is designed to create secure connections among hospitals and serve as a blueprint for collaborative clinical research using advanced privacy technologies. Initial deployment will be in partner hospitals in Italy and Switzerland, with the aim of expanding to the global Pediatric Emergency Research Network. Through that expansion Tune Insight expects to access data from over 100 hospitals and about 2 million pediatric emergency presentations yearly. The company has received recognition in Swiss startup programs and has engaged in seed fundraising activities to support growth. Tune Insight builds a platform that orchestrates secure collaborations on sensitive or confidential data across organisations, domains, and jurisdictions, enabling collective analytics, federated machine learning and approved computations while protecting data in use. The technology applies applied cryptography and privacy-enhancing technologies and was spun out of several years of research at the Swiss Federal Institute of Technology (EPFL) to address personalised healthcare collaboration without transferring patient data. Tune Insight is deployed at University Hospital Zurich, CHUV in Lausanne, Inselspital in Bern and University Spital Basel, powering use cases such as survival analysis for precision oncology and the generation of personalised reference ranges. Its reference-range application leverages a collective dataset of 9 million data points from over 250,000 patients. The platform is also used in law, financial services and cybersecurity, and Tune Insight is extending support for privacy-preserving generative AI. The company aims to reduce data liability, streamline compliance and reinforce data security while enabling cross-jurisdictional collaboration. Tune Insight offers a software solution that lets groups of organizations run collective computations on sensitive data while keeping individual data on each organization’s premises. Its platform uses multiparty homomorphic encryption to perform computations under encryption and only release authorized final results. Customers can define the partner group, the data types to share, and the permitted operations and functionalities for that group. The product targets sectors that cannot freely share data for strategic or regulatory reasons, including health, insurance and cybersecurity. The company plans to expand its development team and create a sales and customer-satisfaction team to move from proofs-of-concept and pre-scale deployments toward recurring licensing revenue. The approach is rooted in years of EPFL research and emphasizes compliance with personal data laws and mitigation of data-leak risks. Tune Insight builds infrastructure-agnostic B2B software that enables secure collaborative analytics and machine learning across multiple organizations without transferring raw data. Its platform can be deployed on-premise or in cloud instances and keeps all communications and computations encrypted. The software enables federated scenarios where participants retain full control of their own data while extracting collective insights. The company emphasizes privacy-enhancing technologies (including homomorphic encryption expertise) and says its approach is fully decentralized, widely scalable, and more secure than federated learning without relying on trusted third-party hardware. The founding team includes CEO and co-founder Juan Ramon Troncoso Pastoriza, co-founder and COO Frédéric Pont, Romain Bouyé, and Prof. Jean-Pierre Hubaux, and the team highlights experience with sensitive health data. Tune Insight plans to capture opportunities across multiple domains where firms need to augment their datasets with external data while preserving trust and regulatory compliance. The company closed a pre-seed financing round with Wingman Ventures a few weeks after incorporation.

Led · Seed · Jun 2023

Altis Labs develops Nota, an AI-powered imaging biomarker platform that predicts clinically meaningful outcomes from baseline and follow-up scans to better stratify patients and quantify treatment effect. The company’s deep-learning models are trained on a proprietary cancer imaging database with longitudinal clinical context—reported as over 182 million real-world images—and aim to move beyond simplistic tumor-size measurements. Biopharma customers including Bayer use Nota to analyze imaging from phase 1–3 trials, and Altis says its imaging-based prognostication (IPRO) technology has been validated in collaborations published in the Journal of Clinical Oncology and presented at ASCO. Funding will be used to scale development of Nota across solid tumor types and therapeutic areas. Altis positions its software as a tool to generate higher-quality evidence earlier in development, inform go/no-go and trial design decisions, and improve late-stage success rates. The company is proudly based in Toronto, Canada.